These improvements include: Gastrointestinal Benefits: Reduced chronic diarrhea and abdominal cramping Improved tolerance to previously triggering foods Decreased bloating and digestive discomfort Better overall gut stability Systemic Improvements: Reduction in chronic fatigue and brain fog Decreased frequency and severity of flushing episodes Improved sleep quality and energy levels Better exercise tolerance without triggering flares Skin and Respiratory Changes: Fewer spontaneous hives and skin reactions Reduced respiratory symptoms and wheezing Less reactive responses to environmental triggers Improved overall symptom stability What particularly strikes me is the timing of these improvements
These medications target the GLP-1 pathway, influencing feelings of hunger and fullness to promote sustainable weight loss
Adequate Sleep Testosterone is naturally restored during sleep, and poor sleep can increase cortisol levels, negatively affecting weight loss
These gastrointestinal symptoms are not uncommon with this class of medications, particularly when the drug is started, or the dose is increased
Stimulants are classified as controlled substances
The first structure of a class B GPCR transmembrane (TM) domain was solved recently, but the full length receptor structure is still not well understood